As patients with diabetes progress throughout their lives there may be a need to increase treatment to help manage their symptoms. A recent study looked at how likely patients are to intensify their treatment and what that can mean for their care.
Patients in the open-label extension phase of RIDE/RISE who needed Lucentis less frequently tended to have less advanced diabetic macular edema (DME) at extension baseline and to respond better to initial treatment, according to post hoc analysis. These results suggest that earlier treatment of center-involving DME with loss of visual acuity may decrease its long-term treatment burden.
Patients with diabetes face many challenges over the course of a day, not the least of which is ensuring their blood glucose levels stay in a safe range. Technological advances have helped make this an easier obstacle to overcome.
While technology is helping patients with diabetes improve their quality of life there is only so much that technology and their health care providers can do for them. In many ways a patient can and must now play a larger role in their overall care.
With so many patients dealing with diabetes on a daily basis the burden of trying to help can be too much for even the biggest and most advanced companies. By working together they can not only reach more patients but also provide a higher level of care.
Although intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become the therapeutic mainstay for diabetic macular edema and neovascular age-related macular degeneration, it poses a risk of noninfectious uveitis or infectious endopthalmitis.
A retrospective analysis of diabetes and prediabetes diagnoses found that screening guidelines from the United States Preventative Service Task Force (USPSTF) would have detected less than half of all cases that were discovered.
Diabetes may have its roots in endocrinology but in recent years it has proven to be an issue affecting specialities across medicine. Because of that it takes more than one specialist to provide the best possible care for patients with the condition.
At the recent American Diabetes Association annual meeting Lilly Diabetes had more than 60 disclosures discussing their latest work in the field. Of all that work the Mosaic study was arguably the biggest news to come out of New Orleans.